The 66th ASH Annual Meeting and Exposition is now just one week away! From December 7-10th 2024, San Diego, California is set to welcome over 30,000 health professionals, clinicians, researchers, educators and over 275 exhibitors, both in person and online, from around the world, making it the world’s largest event in hematology. The conference is set to showcase the most innovative research and cutting-edge science driving the future of haematology and shaping patient care.
This year’s programme is designed to meet the diverse needs across both malignant and classical haematology, with hundreds of sessions covering the latest advances in every specialty, offering something for all the global haematology community.
touchHAEMATOLOGY are excited to be covering the conference through a series of interviews with leading experts in the field. Keep your eyes peeled on the Conference Hub for the latest from #ASH24!
Breaking news! Late-breaking abstracts are now available!
With almost 8,000 abstracts accepted – a new record – click here to view the 5,000+ accepted unseen abstracts representing the most cutting-edge science in haematology
View the Scientific Programme
Hot Topics
- Milestones and progress in understanding sickle cell disease
- Global hematology challenges and solutions
- Innovations in cell therapy
- New insights into thrombosis and haemostasis
- Gene therapy and genome editing
- Artificial intelligence in hematology
- The latest in CAR-T therapy and immunotherapies
- and much, much more!
For more information and information on how to register, visit the #ASH24 congress website.
About the American Society of Hematology
The American Society of Hematology (ASH) is the world’s leading professional organization uniting clinicians and scientists committed to advancing the fight against blood disorders. Since its establishment in 1958, ASH has been at the forefront of shaping haematology as a discipline, driving progress in research, patient care, education, training and advocacy.
Disclosure: This article was created by the touchHAEMATOLOGY team utilizing AI as an editorial tool (ChatGPT (GPT-4o) [Large language model]. https://chat.openai.com/chat.) The content was developed and edited by human editors. No funding was received in the publication of this article.
